查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604727

異位性皮膚炎治療市場：按藥物類別、給藥途徑分類 - 2025-2030 年全球預測

Atopic Dermatitis Drugs Market by Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids), Route of Administration (Injectable ROA, Oral ROA, Tropical ROA) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年異位性皮膚炎治療市值為80.2億美元，預計到2024年將達到85.6億美元，複合年成長率為6.84%，到2030年將達到127.6億美元，預計將達到1000萬美元。

異位性皮膚炎 (AD) 藥物包括控制和治療異位性皮膚炎症狀的藥物。異位性皮膚炎是一種慢性發炎皮膚病，其特徵是皮膚發癢和發炎。這些藥物的需求源於異位性皮膚炎的全球流行，該疾病影響兒童和成人，並且需要有效的治療方法。應用範圍主要是局部、全身用藥和生物製藥，最終用戶包括醫院、藥房、線上零售商和皮膚科診所。關鍵的成長要素包括皮膚健康意識的提高、醫療保健支出的增加、生物技術的進步以及單株抗體和 JAK 抑制劑等創新藥物產品線的不斷擴大。最近的機會包括擴大使用針對高度特異性發炎途徑的生物製藥，以及個人化醫療根據基因譜量身訂做治療的潛力。然而，市場開拓面臨著高昂的藥物開發成本、監管障礙、大規模臨床試驗的需要、競爭激烈的市場動態以及與某些治療相關的潛在副作用等挑戰。為了抓住新的機遇，相關人員正在推動研究和開發，以開發更有效、更安全的生技藥品，探索自然療法和替代療法，並利用數位療法來監測和管理 AD 症狀。積極參與合作研究和夥伴關係可以促進知識轉移和創新突破。此外，技術創新的目標是生產更具成本效益的配方並使其更容易獲得。該市場競爭激烈、研究密集型，並且由於科學進步和以患者為中心的需求而不斷發展，需要靈活的策略才能保持市場領先地位。

主要市場統計
基準年[2023] 80.2億美元
預測年份 [2024] 85.6億美元
預測年份 [2030] 127.6億美元
複合年成長率（%） 6.84%

市場動態：快速發展的異位性皮膚炎治療市場的關鍵市場洞察

供需的動態交互作用正在改變異位性皮膚炎藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 異位性皮膚炎盛行率增加
    • 食物過敏盛行率增加，導致異位性皮膚炎惡化
    • 開發保護皮膚屏障的新型保濕劑、生技藥品及局部補脂藥物
  • 市場限制因素
    • 治療藥物高成本
  • 市場機會
    • 治療方法意識不斷增強
    • 增加各個開發中國家獲得治療的機會
  • 市場挑戰
    • 與藥物相關的副作用

波特五力：駕馭異位性皮膚炎藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解異位性皮膚炎治療藥物市場的外部影響

外部宏觀環境因素在塑造異位性皮膚炎治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解異位性皮膚炎治療藥物市場的競爭狀況

對異位性皮膚炎治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣異位性皮膚炎治療市場供應商的績效評估

FPNV 定位矩陣是評估異位性皮膚炎治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪異位性皮膚炎治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對異位性皮膚炎治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 異位性皮膚炎的發生率增加
      • 食物過敏的增加正在加劇異位性皮膚炎
      • 保護皮膚屏障的新型保濕劑、生技藥品、外用補脂藥物的開發
    • 抑制因素
      • 治療費用上漲
    • 機會
      • 提高對該疾病治療方法可用性的認知
      • 擴大各個新興國家獲得治療的機會
    • 任務
      • 與藥物使用相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 異位性皮膚炎治療藥物市場（依藥物類別）

  • 生物製藥
  • Calcineurin抑制劑
  • 皮質類固醇
  • 磷酸二酯酶4抑制劑

第7章 異位性皮膚炎治療藥物市場：依給藥途徑

  • 可注射的ROA
  • 口服ROA
  • 熱帶ROA

第8章 北美和南美異位性皮膚炎治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太特應性皮膚炎治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲異位性皮膚炎治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galderma SA
  • GlaxoSmithKline PLC
  • LEO Pharma A/S
  • Meda AB
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-436901065D12

The Atopic Dermatitis Drugs Market was valued at USD 8.02 billion in 2023, expected to reach USD 8.56 billion in 2024, and is projected to grow at a CAGR of 6.84%, to USD 12.76 billion by 2030.

Atopic dermatitis (AD) drugs encompass therapeutic medications designed to manage and treat the symptoms of atopic dermatitis, a chronic inflammatory skin condition marked by itchy and inflamed patches of skin. The necessity for these drugs is driven by the significant prevalence of atopic dermatitis globally, which impacts both pediatric and adult populations, leading to demand for effective treatments that offer relief and improve life quality. The application scope primarily covers topical treatments, systemic drugs, and biologics, with end-users ranging from hospitals, pharmacies, online retailers, and dermatology clinics. Key growth factors include heightened awareness of skin health, increased healthcare expenditure, advancements in biotechnology, and a growing pipeline of innovative drugs such as monoclonal antibodies and JAK inhibitors. Recent opportunities emerge from expanding the use of biologics, which target inflammation pathways with high specificity, and the potential for personalized medicine, which tailors treatments based on genetic profiles. However, market growth is challenged by high drug development costs, regulatory hurdles, and the need for extensive clinical trials, coupled with competitive market dynamics and potential side effects associated with some treatments. To seize emerging opportunities, stakeholders should focus on investing in R&D that pushes for the development of more effective and safer biologics, exploring natural and alternative remedies, and leveraging digital therapeutics for monitoring and managing AD symptoms. Proactive engagement in collaborations and partnerships can facilitate knowledge transfer and innovative breakthroughs. Moreover, innovation could aim at creating more cost-effective formulations to broaden accessibility. The nature of the atopic dermatitis drugs market is highly competitive and research-intensive, characterized by constant evolution driven by scientific advancements and patient-centric demand, necessitating agile strategies to stay ahead in the market.

KEY MARKET STATISTICS
Base Year [2023] USD 8.02 billion
Estimated Year [2024] USD 8.56 billion
Forecast Year [2030] USD 12.76 billion
CAGR (%) 6.84%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Atopic Dermatitis Drugs Market

The Atopic Dermatitis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of atopic dermatitis
    • Growing prevalence of food allergies intensifying atopic dermatitis
    • Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
  • Market Restraints
    • High cost of therapeutics
  • Market Opportunities
    • Rising awareness regarding the availability of treatments for the disease
    • Growing access to treatment in various developing countries
  • Market Challenges
    • Adverse effects associated with the use of medication

Porter's Five Forces: A Strategic Tool for Navigating the Atopic Dermatitis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Atopic Dermatitis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Atopic Dermatitis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Atopic Dermatitis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Atopic Dermatitis Drugs Market

A detailed market share analysis in the Atopic Dermatitis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Atopic Dermatitis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Atopic Dermatitis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Atopic Dermatitis Drugs Market

A strategic analysis of the Atopic Dermatitis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Atopic Dermatitis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma S.A., GlaxoSmithKline PLC, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Atopic Dermatitis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Biologics, Calcineurin Inhibitors, Corticosteroids, and Phosphodiesterases 4 Inhibitors.
  • Based on Route of Administration, market is studied across Injectable ROA, Oral ROA, and Tropical ROA.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of atopic dermatitis
      • 5.1.1.2. Growing prevalence of food allergies intensifying atopic dermatitis
      • 5.1.1.3. Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising awareness regarding the availability of treatments for the disease
      • 5.1.3.2. Growing access to treatment in various developing countries
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with the use of medication
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Atopic Dermatitis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Calcineurin Inhibitors
  • 6.4. Corticosteroids
  • 6.5. Phosphodiesterases 4 Inhibitors

7. Atopic Dermatitis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable ROA
  • 7.3. Oral ROA
  • 7.4. Tropical ROA

8. Americas Atopic Dermatitis Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Atopic Dermatitis Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Atopic Dermatitis Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bausch Health Companies Inc.
  • 3. Bayer AG
  • 4. Biofrontera AG
  • 5. Bristol-Myers Squibb Company
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Galderma S.A.
  • 9. GlaxoSmithKline PLC
  • 10. LEO Pharma A/S
  • 11. Meda AB
  • 12. Mylan N.V.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Regeneron Pharmaceuticals, Inc
  • 16. Sanofi S.A.
  • 17. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ATOPIC DERMATITIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ATOPIC DERMATITIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ATOPIC DERMATITIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ATOPIC DERMATITIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PHOSPHODIESTERASES 4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE ROA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ORAL ROA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TROPICAL ROA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023